A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients

Ikuo Sekine, Yasushi Shintani, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Hirotoshi Dosaka-Akita, Yuichi Takiguchi, Etsuo Miyaoka, Meinoshin Okumura (+1 others)
2020 Cancer Science  
This study provided the benchmark statistics on medically treated patients with non-small cell (NSCLC) and small cell (SCLC) lung cancer in Japan. Demographic background, treatment, and prognosis were obtained from patients with lung cancer pathologically diagnosed in 2012, who received non-surgical treatment. Descriptive statistics and their associations with survival were analyzed. A total of 12320 patients were registered from 314 institutions in Japan. The median age was 70 years, and 73%
more » ... the patients were male. The number (%) of stage I, II, III, IV diseases were 468 (3.8%), 421 (3.4%), 3260 (26.5%), and 8171 (66.3%), respectively. NSCLC and SCLC accounted for 9872 (80.1%) and 2353 (19.1%) patients, respectively. Thoracic radiotherapy-based therapy, chemotherapy, and palliative care alone were administered to 2572 (20.9%), 7790 (63.2%), and 1952 (15.8%) patients, respectively. Clinical TNM stage was one of the strongest prognostic factors with the 3-year survival rates of 62.9%, 47.3%, 40.0%, 27.8%, 37.5%, 26.5%, and 18.2% for stage IA, IB, IIA, IIB, IIIA, IIIB, and IV, respectively. Among 6158 NSCLC patients treated with chemotherapy, the 3-year survival rate was 33.4% in patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) at some point in their clinical course, whereas it was 17.4% in patients who did not. The 3-year survival rate of SCLC was only 15.9%. In conclusion, approximately two-thirds of the patients were diagnosed as stage IV at the initial diagnosis. Use of EGFR-TKIs significantly improved the survival of patients with NSCLC.
doi:10.1111/cas.14368 pmid:32103551 fatcat:unrxglhkznhkdc4ml5fjyg2sea